Key Takeaway: Johnson & Johnson has announced a partnership with Elektrofi, a Boston-based biotech firm, which aims to enhance drug delivery systems. Additionally, Enyo has successfully raised €39 million to support its research initiatives. The article also briefly mentions updates from TC BioPharm, BioCentrIQ, 4D Molecular, Arbor Biotechnologies, and Longboard Pharmaceuticals.
Price reaction · baseline $18.685 (2024-01-11T15:44:00.000Z) · hit during market hours · 1 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Johnson & Johnson's partnership with Elektrofi could enhance drug delivery.
The collaboration may lead to innovative biopharmaceutical solutions.
Increased funding for Enyo could boost its research capabilities.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
ENDPOINTS
Plus, news about TC BioPharm, BioCentriq, 4D Molecular and Arbor Biotechnologies, and Longboard Pharmaceuticals:
Johnson & Johnson teams up with Elektrofi: The Boston biotech
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Frequently Asked Questions
What is the focus of J&J's partnership with Elektrofi?
The partnership aims to enhance drug delivery systems.
How much funding did Enyo raise?
Enyo successfully raised €39 million for its research initiatives.
Which other companies are mentioned in the article?
The article mentions TC BioPharm, BioCentrIQ, 4D Molecular, Arbor Biotechnologies, and Longboard Pharmaceuticals.